Definium Therapeutics, Inc.
DFTX Nasdaq· Medicinal Chemicals & Botanical Products
Last close · Oct 23, 2026
$35.67
KIRA · Stoqly’s AI analyst, in plain words
- Definium Therapeutics, Inc. lost $184M in fiscal 2025.
- Definium Therapeutics, Inc. has $371M more cash than debt.
Market cap
$3.9B
P/E
—
Revenue
—
Net income
−$184M
Free cash flow
—
Operating margin
—
Definium Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$184M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Definium Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Definium Therapeutics, Inc.
- CIK
- 0001813814
Definium Therapeutics, Inc. · DFTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.4M | $1.5M | $4.7M | — | — |
| Revenue growth | — | — | 212.0% | — | — |
| Net interest income | −$0.4M | $1.5M | $4.7M | — | — |
| Operating margin | 26,143.2% | −4,436.9% | −2,012.6% | — | — |
| Net income | −$93.0M | −$56.8M | −$95.7M | −$109M | −$184M |
| Net margin | 25,915.3% | −3,799.1% | −2,052.6% | — | — |
| Diluted EPS | −$3.40 | −$1.84 | −$2.44 | −$1.54 | −$2.06 |
| Cash | |||||
| Cash from operations | −$45.8M | −$50.1M | −$64.4M | −$79.1M | −$132M |
| Share count change | −89.7% | 12.7% | 26.9% | 79.9% | 26.8% |
| Debt and strength | |||||
| Cash and short-term investments | $134M | $142M | $99.7M | $274M | $412M |
| Debt incl. finance leases | — | — | $14.1M | $21.9M | $40.6M |
| Shareholders' equity | $152M | $151M | $78.1M | $241M | $332M |
| Current ratio | 13.2x | 8.2x | 3.2x | 7.2x | 6.3x |
| Interest coverage | — | — | −102.0x | −45.5x | −30.3x |
| Returns and quality | |||||
| Return on equity | −81.8% | −37.5% | −83.6% | −68.0% | −64.1% |
| Return on tangible equity | −74.5% | −44.6% | −165.9% | −49.1% | −58.8% |
| Piotroski F-score | 2 | 3 | 2 | 4 | 1 |
| Altman Z'' | 11.4 | 6.9 | −7.1 | 2.8 | 1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$7.0M
5 insiders
Of sales under plans
100%
$7.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Definium Therapeutics, Inc. · DFTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $35.67 a share, the company is worth $3.9B.
Source: SEC EDGAR XBRL filings (CIK 0001813814). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.